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Abstract: Appropriate antibiotic treatment for respiratory 
tract infections (RTIs) necessitates rapid and accurate 
diagnosis of microbial etiology, which remains challeng-
ing despite recent innovations. Several host response-
based biomarkers due to infection have been suggested 
to allow discrimination of bacterial and non-bacterial 
microbial RTI etiology. This review provides an overview 
of clinical studies that investigated the diagnostic perfor-
mance of host-response proteomic biomarkers to iden-
tify RTI microbial etiology. Procalcitonin and C-reactive 
protein have been studied most extensively; whereof 
procalcitonin has demonstrated the strongest diagnos-
tic performance compared to other biomarkers. Proad-
renomedullin, soluble triggering receptor expressed on 
myeloid cells-1, neopterin and pentraxin-3 need more 
studies to confirm their diagnostic value. For syndecan-4 
and lipocalin-2 currently insufficient evidence exists. 
Common limitations in several of the studies were the rel-
atively small scale setting, heterogeneous patient popula-
tion and the absence of statistical power calculation.
Keywords: biomarkers; diagnosis; etiology; immunore-
sponse; respiratory infections.
Introduction
Respiratory tract infections (RTIs), particularly those 
affecting the lower respiratory tract, are major causes 
of hospitalization and mortality in children and adults 
[1]. RTIs can be of bacterial or viral origin, with a strong 
overlap in clinical signs and symptoms. Bacterial RTIs, 
compared to viral RTIs, often do not resolve spontane-
ously, thus requiring antibiotic treatment [2]. To this end, 
standard clinical practice initiates an empiric antibiotic 
treatment covering the most likely pathogens involved 
[1]. This empiric treatment often is applied for prolonged 
periods due to significant turnaround times of the current 
diagnostic approaches.
Current limitations of diagnostic tools translate into 
sub-optimal use of antibiotics. Clinicians may decide to 
continue empiric antibiotic therapy to mitigate the risk of 
false negative results associated with current diagnostics. 
A study in the US showed that 30% of pediatric patients 
without a confirmed bacterial infection still received anti-
biotics [3]. Unnecessary use of antibiotics will increase the 
risk of side effects and promote the development of antibi-
otic resistance. Improving diagnostic tools and biomark-
ers to support the diagnosis of bacterial RTIs is therefore 
highly relevant.
The identification of RTI microbial etiology is based 
on microbial culturing of biofluids and targeted tech-
niques such as antigen testing and detection of pathogen 
DNA using polymerase chain reaction (PCR). The signifi-
cant turnaround time of >48 h for microbiological cultures 
represents a known challenge. Other challenges include 
incorrect diagnostic conclusions due to colonization and 
limitations to the sensitivity to detect pathogens, espe-
cially with fastidious bacteria and during an ongoing anti-
biotic treatment [4]. PCR technologies to detect genetic 
material of pathogens in biofluids are rapidly developing 
as an important diagnostic tool for bacterial infections 
including RTIs [4]. The advantages of PCR technology 
include its sensitivity and specificity in the presence of 
ongoing antibiotic therapy, simultaneous detection of 
multiple pathogens using multiplex PCR, and improved 
turnaround times of 1–6  h [4]. Limitations include 
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intrinsic specificity to specific pathogens, the practical 
burden of processing samples for PCR analysis, and the 
possibility to lead to false-positive results associated with 
 colonization [4].
Host- or immune-response biomarkers measured in 
blood and other biofluids are of interest as they may 
support rapid discrimination between bacterial and viral 
etiology in RTIs. While host-response biomarkers are 
unlikely to differentiate between pathogens at the level 
of specificity such as PCR, they may support discrimina-
tion of bacteria vs. viral infections and potentially large 
classes (e.g. Gram-negative or Gram-positive), which can 
thus support rapid elimination of antibiotic use when no 
bacterial etiology is present. In addition, longitudinal 
measurements of such biomarkers may potentially quan-
tify treatment response or failure. We provide an overview 
of current clinical evidence that supports the use of host-
response proteomic biomarkers to establish the micro-
bial etiology in patients with suspected RTIs, focusing on 
studies with supporting microbiological evidence of RTI 
etiology.
Host response biomarkers to detect 
bacterial infections
An overview of identified host response biomarkers in 
RTI patients is provided in Table 1. This includes a brief 
description of the study design, study population, the bio-
logical matrix sampled to quantify the biomarkers, bio-
markers’ cut-off value and metrics to evaluate diagnostic 
performance of RTI etiology in terms of sensitivity, speci-
ficity and area under receiver operating curve (AUROC).
C-reactive protein
C-reactive protein (CRP) is well established as an inflam-
matory marker associated with infection but also other 
inflammatory conditions. CRP increases more extensively 
during bacterial than non-bacterial RTIs [19] and is regu-
larly used in clinical practice for diagnosing RTI microbial 
etiology. CRP-guided diagnosis was shown to reduce initial 
antibiotic prescriptions by approximately 20% in a meta-
analysis of 13 randomized controlled trials (RCTs) involv-
ing 10,005 adult RTI patients [15]. However, CRP remains 
a non-specific inflammatory biomarker with insufficient 
specificity and sensitivity for bacterial RTIs. Moreover, 
CRP levels might not reflect the bacterial disease load or 
disease progression accurately due to its relatively slower 
increase and decline rates (i.e. kinetics) in blood [20] com-
pared to the bacterial load.
Procalcitonin
Procalcitonin levels in blood increase following bacte-
rial infection and decline following adequate treatment 
with antibiotics [20]. Procalcitonin increases more exten-
sively during bacterial than in viral RTIs and has a more 
responsive kinetic profile, potentially reflecting the bacte-
rial disease progression compared to CRP [20, 21]. These 
advantages supported the use of procalcitonin as a bac-
terial infection diagnostic biomarker including RTIs to 
guide antibiotics initiation and termination [21].
Procalcitonin has been studied as an intervention 
biomarker in RCTs, where procalcitonin levels in blood 
determined the initiation and discontinuation of antibi-
otic treatment. Procalcitonin-guided antibiotic treatment 
protocols were associated with a decrease of 19% in the 
antibiotic prescription rate (p < 0.0001) and 30% in overall 
exposure days to antibiotics (p < 0.0001) in a recent sys-
tematic review and meta-analysis involving patients with 
acute respiratory infections [16]. Similar rates of treat-
ment failure and length of ICU or hospital stay were found 
between the procalcitonin and the control groups. Inter-
estingly, a lower 30-day morality rate (p < 0.05) and anti-
biotic side effects (p < 0.0001) were observed within the 
procalcitonin group. A meta-analysis based on two RCTs of 
655 upper RTI patients showed that procalcitonin was asso-
ciated with a decrease in the antibiotic prescription rate 
from 51% in the control group to 18% in the procalcitonin 
group [22]. No significant differences in clinical outcomes 
such as treatment failure, mortality or days with restricted 
activity were found between the procalcitonin and the 
control groups. Current challenges that limit application 
of PCT include the determination of optimal diagnostic 
cutoff values to diagnose bacterial RTIs, and the impact of 
various patient conditions on these values, which should 
be studied in stratified randomized clinical studies.
Proadrenomedullin
Proadrenomedullin serves as a biomarker for indirect 
quantification of adrenomedullin. Adrenomedullin plays 
a vital role in immune-modulation, and its serum level 
increases during bacterial and viral infections [23]. The 
evidence of proadrenomedullin to support the diagnosis 
of bacterial RTIs is inconsistent. One study with pediat-
ric patients with complicated and bacteremia-associated 
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pneumonia vs. pleural empyema showed 100% sensitivity 
and could accurately distinguish between these patient 
groups (AUROC >0.85) with a sensitivity and specificity com-
parable to CRP [9]. However, no specific statistical power 
calculation was performed as this study was a secondary 
analysis. Another study that compared the utility of proad-
renomedullin to predict bacterial community-acquired 
pneumonia (CAP) vs. non-bacterial RTIs did not show the 
predictive relevance of proadrenomedullin [5]. In summary, 
prospective studies with a larger and more uniform patient 
population can support establishing the relevance of proad-
renomedullin in identifying bacterial etiology of RTIs.
sTREM-1
Soluble triggering receptor expressed on myeloid cells-1 
(sTREM-1) levels rise in biofluids after an increase of 
TREM-1 expression on neutrophils, granulocytes, mono-
cytes and alveolar macrophages in normal lung tissue 
[24]. TREM-1 regulates inflammatory responses associated 
with monocytes and neutrophils [24]. Microbial products 
increase TREM-1 expression with a subsequent increase of 
sTREM-1 levels in the biofluids [24].
A meta-analysis of nine studies showed that bron-
choalveolar lavage fluid (BALF) sTREM-1 could identify 
bacterial RTIs with high accuracy [8]. BALF sTREM-1 was 
higher only in pneumonia patients with positive BALF 
cultures (100% specificity) and could accurately differen-
tiate them from pneumonia patients with negative BALF 
cultures (AUROC > 0.85). Furthermore, BALF sTREM-1 
outperformed plasma sTREM-1 that failed to distinguish 
both conditions [6]. However, another study in patients 
with respiratory insufficiency and bacterial infections 
only reported a moderate diagnostic performance [25]. For 
comparison of bacterial vs. viral CAP in pediatric patients, 
plasma sTREM-1  showed very low sensitivity [5]. In 
patients with bacterial and non-infectious lung infiltrates, 
serum sTREM-1 levels were reported to be highly sensitive 
and with moderate discriminatory power [10]. However, 
the control group of this study missed patients with lung 
infiltrates due to viral infections that are associated with 
elevated sTREM-1 levels [6, 8].
In conclusion, the choice of sTREM-1 biological matrix 
may be related to the accuracy of sTREM-1 diagnostic per-
formance of microbial etiology; the results favor the use 
of BALF over serum sTREM-1. Despite inconsistency of 
sTREM-1 cutoff values, which might affect sensitivity and 
specificity with no real variation of accuracy [26], these 
results foster further investigation of BALF sTREM-1 diag-
nostic value in RTIs.
Pentraxin-3
Pentraxin-3 is an acute inflammatory marker and a vital 
component of innate immunity [27]. Pathogens stimulate 
pentraxin-3 production in different cells including epithe-
lial, endothelial, myeloid dendritic cells, neutrophils and 
macrophages [27]. Pentraxin-3 promotes the recruitment 
of neutrophils [27].
Studies suggest the potential diagnostic value of pen-
traxin-3 in RTIs. Sputum pentraxin-3 levels were higher in 
chronic inflammatory pulmonary disease (COPD) patients 
with bacterial exacerbations compared to those with viral 
and non-infectious exacerbations [7]. However, COPD is 
an inflammatory state that could potentially affect levels 
of the inflammatory marker pentraxin-3, the effect of COPD 
per se on pentraxin-3 levels requires further investigation. 
BALF pentraxin-3 was associated with good performance 
and >90% sensitivity to discriminate patients with culture 
positive – bacterial, viral or fungal – and culture nega-
tive pneumonia at a cut-off of >1 ng/mL [13]. At a cut-off 
of >7 ng/mL, BALF pentraxin-3 performed similarly and 
identified the subgroup of patients with proven bacterial 
pneumonia. The non-homogenous patient population 
involving CAP, hospital-acquired pneumonia, health-care 
associated pneumonia and ventilator-associated pneumo-
nia patients may have affected the sensitivity and specific-
ity of BALF pentraxin-3.
Syndecan-4
Syndecan-4, a member of the heparin sulfate proteo-
glycans is ubiquitously present on many cells including 
alveolar macrophages and might play a role in RTIs [28]. 
Patients with mild acute pneumonia showed approxi-
mately 60% higher syndecan-4 levels compared to healthy 
controls, but also to patients with severe pneumonia [29]. 
Syndecan-4 levels declined gradually when the patients 
received adequate antibiotics. However, a limitation of 
this study was that a comparison of pneumonia patients 
to healthy volunteers was made without identifying the 
etiology of pneumonia, i.e. bacterial or viral. The conflict-
ing difference between higher syndecan-4 levels in mild 
vs. severe pneumonia is unexpected and raises questions 
about the validity of the study findings. In another study 
in pediatric patients with bacterial or viral CAP, synde-
can-4  showed poor discriminatory power (AUROC ≈ 0.5) 
[14]. However, the viral pneumonia subgroup in this 
study was underrepresented (16 patients) compared to the 
bacterial subgroup (74 patients). Therefore, more exten-
sive studies, which are adequately powered and with 
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predefined microbial etiology of RTI patients involved, are 
required to further assess the relevance of this potential 
biomarker to bacterial RTI.
Lipocalin-2
Lipocalin-2 levels increase during infection and inflam-
mation; lipocalin-2 plays a key role in innate immunity 
through interference with bacterial iron uptake [30]. In 
pediatric patients with bacterial and viral pneumonia, 
lipocalin-2 failed to discriminate between these groups 
(AUROC ≈ 0.5) [14]. Here, lipocalin-2  was studied in the 
same study as syndecan-4, which under-represented 
the viral pneumonia group. Therefore, more evidence is 
required to assess the diagnostic relevance of lipocalin-2 
in RTIs.
Midregional proatrial natriuretic peptide
Midregional proatrial natriuretic peptide (MR-proANP) is a 
byproduct of atrial natriuretic peptide (ANP) biosynthesis, 
and is used as a surrogate for ANP quantification, which 
has a half-life as short as 4 min in contrast to the 90-min 
half-life of MR-proANP. ANP regulates macrophages activ-
ity in innate and acquired immunity [31].
MR-proANP has demonstrated low performance as a 
diagnostic biomarker of bacterial RTIs. In two studies of 
bacterial and non-bacterial RTIs pediatric patients, MR-
proANP failed to differentiate between these two groups [5, 
32]. However, in adult patients with lower RTIs, increased 
values for MR-proANP in comparison to adult healthy con-
trols have been reported [17]. Furthermore, in this study, 
CAP patients had significantly higher MR-proANP levels 
than patients with other RTIs. RTI patients with bactere-
mia had higher MR-proANP levels than patients without 
bacteremia. However, MR-proANP showed low ability to 
discriminate between blood culture positive and negative 
adult mild CAP patients [33].
The current evidence does not support MR-proANP 
as a biomarker of bacterial RTIs. However, different study 
populations may have caused variation of MR-proANP 
levels among the studies as MR-proANP is also affected by 
age and heart conditions [34].
Copeptin
Copeptin, a more stable byproduct of vasopressin biosyn-
thesis, serves as a biomarker of vasopressin quantification. 
Bacterial endotoxins induce an increase of vasopressin 
levels in blood [35]. The low ex-vivo stability and platelets 
binding limits vasopressin potential for quantification 
and use as a biomarker of RTI [35].
In pediatric patients with uncomplicated CAP and 
CAP complicated with bacteremia and/or empyema, 
copeptin was not identified as a relevant biomarker [9]. 
However, this is the same secondary analysis that investi-
gated sTREM-1 and copeptin and was not associated with 
statistical power calculation. Another study showed that 
copeptin levels were significantly higher in adult patients 
with respiratory conditions including CAP, COPD, bron-
chitis and asthma compared comparison to healthy con-
trols [18]. Particularly, copeptin was significantly higher 
in patients with positive blood cultures. However, the 
absence of microbiological evidence of RTI microbial eti-
ology, – e.g. bacterial culture or PCR results  −  limits the 
results of these studies. Empyema and bacteremia are 
systemic infectious complications of RTIs; their presence 
or absence does not confirm or rule out bacterial RTIs in 
patients.
Neopterin: a pteridine biomarker
Neopterin is produced in monocytes and macrophages 
and represents a marker of cell-mediated immunity [36]. 
Neopterin serum levels increase during inflammation 
[36] and viral RTIs [11, 12]. Neopterin showed potential 
to diagnose a viral etiology of RTIs in two studies that 
compared healthy subjects, and bacterial and viral RTIs 
patients. Median serum neopterin levels in patients with 
viral RTIs were 200% higher compared to bacterial RTIs 
[11, 12]. However, both studies had the same study design 
and were performed in the same hospital in Hong Kong; 
multicenter studies could further confirm the relevance of 
neopterin to identify the microbial etiology of RTIs.
Discussion
Several host-response protein-based biomarkers have 
been investigated in the last decade to discriminate 
between bacterial and non-bacterial RTIs. Procalcitonin 
and CRP have been studied most extensively. Procalcitonin 
may have the strongest performance compared to other 
biomarkers. Proadrenomedullin, neopterin, sTREM-1 and 
pentraxin-3 warrant future studies to confirm their diag-
nostic value. The available evidence does not support the 
use of syndecan-4 and lipocalin-2 as biomarkers of bacte-
rial or viral RTIs. Limitations in study design and sample 
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size limited for several biomarkers, the ability to draw 
meaningful conclusions.
The absence of a reliable sensitive and specific “gold 
standard” to support diagnosis of the microbial etiology 
of RTIs remains a major challenge in the interpretation 
of observational studies that aim to identify biomarkers. 
In our review, studies relied mainly on culture-based 
methods as a reference that have inadequate sensitivity 
[37], which further declines after the beginning of antibi-
otic therapy. Alternatively, more sensitive methods such 
as PCR and antigen testing are limited by the intrinsic 
specificity to pathogens and their inability to differentiate 
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Figure 1: Considerations for an optimal diagnostic biomarker of bacterial RTIs.
(A) Correlation between biomarker and bacterial disease progression profile is important for specificity while (B) a lack of correlation 
between non-bacterial (e.g. viral) disease progression should be present. (C) The biomarkers should closely follow the kinetics of disease 
progression.
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latent and active infections. Observational studies that 
investigate novel diagnostic biomarkers that only use a 
single “unreliable” reference test to support diagnosis 
are thus of limited value. Rather, multiple diagnostic 
approaches should be used in combination. The major-
ity of studies reviewed employed multiple diagnostic 
techniques simultaneously, that included examining the 
patients’ clinical presentation, radiology findings, bio-
fluids culture, serology, urinary antigen testing and PCR 
to detect pathogenic DNA. Although these techniques 
identified the exact bacterial species in a considerable 
number of patients, a definite diagnosis often remains 
challenging to obtain [5]. In contrast, interventional 
studies directly evaluating the relationship between clini-
cal outcomes and biomarkers may allow to more defini-
tively identify infection biomarkers [38]. Particularly, 
head-to-head interventional studies biomarkers could 
prioritize biomarkers based on their relative diagnostic 
value. However, concerns over the patients’ safety rep-
resent a persistent challenge for interventional research, 
which should be performed only after the reliability and 
robustness of a certain biomarker to identify RTI micro-
bial etiology have been established in proof-of-concept 
observational studies.
The characterization of the sources of variation in 
individual biomarker concentrations will be crucial to 
improve diagnostic performance. This could be done 
through characterization of the effects of patient-specific 
factors such as age, gender, organ function and drug 
treatment and may be relevant to improve the current 
level of variation that may impair diagnostic perfor-
mance [39]. Elderly and patients with cardiac morbidi-
ties show higher pro-ANP levels [34]. Steroids may lead to 
decreased baseline levels of inflammatory biomarkers. In 
one study, administering prednisone as an adjunct CAP 
treatment was associated with significantly lower CRP 
values. However, procalcitonin levels were not altered 
significantly [40]. Particular caution should be exercised 
when biomarkers are used to identify RTI etiology par-
ticularly in COPD patients who are on constant steroid 
treatment and are at-risk of RTIs. In addition, variation in 
individual biomarker concentrations may also be better 
understood by the consideration of the kinetic nature of 
these protein biomarkers in order to understand the rela-
tionship of the phase of the infections across individual 
patients, which may be very different (Figure 1). Baseline 
(i.e. pre-treatment) biomarker levels may provide infor-
mation on probable RTI etiology guiding antibiotic initia-
tion. The subsequent measurement of the concentrations 
of these biomarkers can provide further insight into the 
progression of the disease course, and after initiation 
of therapy may be used to evaluate treatment response 
and to identify patients with a poor treatment response 
or prognosis [41]. To this end, kinetic biomarker profiles 
can be used to reduce mortality and antibiotic-related 
side effects in RTI patients [16]. Thus, a desirable bio-
marker will demonstrate responsive kinetics; i.e. its level 
in biofluids increases and declines rapidly reflecting the 
disease load.
Diagnostic technologies such as PCR or MALDI-TOF 
that focus on molecular characterization of the pathogen, 
which is both a benefit and a limitation as these assays are 
highly sensitive and specific, but may in some cases detect 
irrelevant pathogens due to colonization or at irrelevant 
disease loads. In contrast, host-response biomarkers aim 
to identify the immunological host-pathogen response 
taking into consideration the association with the actual 
disease state. Host response biomarkers have a less selec-
tive profile with respect to specific molecular pathogen 
characteristics, i.e. until now are focused on classifica-
tion of bacterial or viral infections. In parallel to the role 
of pathogen-focused diagnostics, host-response biomark-
ers may have a clinically relevant role to rapidly stratify 
patients and treatment.
The clinical studies in this review were restricted to 
the potential of host-response biomarkers to differen-
tiate bacterial and nonbacterial RTIs. The potential of 
host-response biomarkers to classify etiology into major 
classes as Gram-positive or Gram-negative bacteria or 
more detailed bacterial species associated with RTIs has 
a large clinical potential and relevance, but remains to be 
investigated. This will potentially support narrowing the 
spectrum of the prescribed antibiotics but should follow 
establishing the potential of one of more of the biomark-
ers to identify patients with bacterial RTIs.
Combining several host-response biomarkers could 
be one way forward to improve diagnostic performance. 
For instance, the combinations of procalcitonin and 
proadrenomedullin increased the probability of diagnos-
ing patients with bacterial RTIs from 0.91 to 0.98 [42]. 
Another two studies showed that CRP/neopterin and 
CRP*procalcitonin/neopterin ratios performed signifi-
cantly better to differentiate adult patients with bacterial 
and viral RTIs compared to CRP, procalcitonin or neop-
terin alone [11, 12]. The latter two studies demonstrate the 
value of combining biomarkers that increase with bacte-
rial RTIs like CRP and procalcitonin and a biomarker that 
increases with viral RTIs as neopterin.
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